Skip to main content

Fiscal Wizard · Single-issue tearsheet

VKTX / Jun 21, 2026 Run #7281

VKTX

Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Composite verdict

F 7.8 / 100
Bearish setup · Mean Reversion 12 drivers · 5 gates blocking
  • Stochastic RSI
  • MA Rejection
  • Vortex Signal
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 475th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 17 signals100% Bear
Momentum Bearish 15Mean-reversion Bearish 36

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

15.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
P/B 75
Free Cash Flow Yield 0
Greenblatt EY 65
EPS Growth (YoY) 0
Return on Equity 25

Technicals Bearish

0.0 / 100

Bearish setup leads (Stochastic RSI, MA Rejection, Vortex Signal); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Stochastic RSI 9
Vortex Signal 11
MA Rejection 14

Risk Gates

5 blocking 4 caution

5 guards active, 20 signals gated.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for VKTX.